Fall is for 5Ks and fundraising! #TeamCastle joined AIM at Melanoma this past weekend to support their 19th Annual KDB Melanoma 5K Run/Walk in Milford, Michigan, helping to raise more than $48k toward ending melanoma. #FallIntoHealthyHabits
Castle Biosciences, Inc.
生物技术研究
Friendswood，Texas 12,695 位关注者
Improving health through innovative tests that guide patient care
关于我们
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx?-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. https://bit.ly/DDx-Melanoma DecisionDx?-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx?-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath? Melanoma and DiffDx?-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher? Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
- 网站
-
https://www.castlebiosciences.com
Castle Biosciences, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 501-1,000 人
- 总部
- Friendswood，Texas
- 类型
- 上市公司
- 创立
- 2008
- 领域
- Diagnostic Cancer Testing、Uveal Melanoma、Cutaneous Melanoma、Melanoma、Skin Cancer、Next Gen Sequencing、Cutaneous Squamous Cell Carcinoma、Gene Expression Profile Tests、Barrett's Esophagus、Esophageal Adenocarcinoma和Dermatologic Cancer
地点
Castle Biosciences, Inc.员工
动态
-
Castle will release Q3 2024 financial results, hosting a conference call and webcast on Monday, November 4th at 4:30 pm ET. For more details and login information, go to https://hubs.la/Q02TgFLz0. #Q3 #earnings
-
-
Castle will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the Oregon Health & Science University (OHSU) Department of Dermatology and being held Oct. 17-21, 2024, in Stevenson, Washington. Details: https://hubs.ly/Q02T4sJ60
-
-
Partner In Prevention spotlight: Castle Biosciences, Inc. ?? For more than a decade, Castle Biosciences and #IMPACTMelanoma have worked together to raise #MelanomaAwareness in Boston, MA, College Station, TX, Friendswood, TX,?and Phoenix, AZ. Our collaboration incorporates many of our programs with a focus on expanding geographically. Our case study explores the remarkable impact: https://bit.ly/3vvAMCn
-
-
?? What is PGx? PGx, or pharmacogenomics, is a groundbreaking field that taps into your unique genetic code (genome) to revolutionize drug treatment. It's like tailoring medication to fit your DNA. Personalized Precision: PGx analyzes your genes to determine the drugs and precise doses that will work best for YOU. Less trial and error, more effective treatment from the start. How Does It Work? Imagine a roadmap for your body's response to mental health medication. PGx deciphers this roadmap by studying your genes, which inform treatments that are compatible with your biology. It's like having a medical strategy uniquely designed for you. #WorldMentalHealthDay #MentalHealthAwareness #PGxtesting #IDgenetix #FallIntoHealthyHabits
-
-
Castle will present new data related to its DecisionDx-Melanoma and DecisionDx?-UM tests for patients with cutaneous melanoma and uveal melanoma, respectively, at the 21st International Congress of the Society for Melanoma Research (SMR), 10/10-13. Details/highlights: https://hubs.ly/Q02SMXYg0
-
-
#TeamCastle has an exciting month ahead! We hope to connect with you at one of these upcoming conferences! DecisionDx-Melanoma DecisionDx-SCC MyPath Melanoma #SMR2024 #ASDS2024 #FallClinical2024
-
-
GROUNDBREAKING NEWS: Castle will host a #groundbreaking ceremony at the site of our new corporate headquarters in Friendswood, Texas on 10/22. Architect Tramonte Design Studio and general contractor O'Donnell/Snider Construction will join us. Full release: https://hubs.la/Q02RRlvC0 Project Team: Partners Real Estate (Developer) Tramonte Design Studio (Architect/Interior Designer) O'Donnell/Snider Construction (General Contractor) SWA Group (Landscape Architect) Fractal Structural Engineering (Structural Engineer) Odyssey Engineering Group, LLC (Civil Engineer) Infinity MEP+S Consultants (MEP Engineer)
-
-
DecisionDx-SCC is a 40-gene expression profile test that uses an individual patient’s tumor biology to stratify risk of metastasis in patients with cutaneous squamous cell carcinoma who have one or more National Comprehensive Cancer Network (NCCN) high-risk factors. More: https://bit.ly/3XM95Q4
-
October is National Depression & Mental Heath Screening month, whose goal is to increase awareness about depression, mental health more broadly, and the importance of mental health screening. #IDgenetix #PGxtesting #MentalHealthAwareness #FallIntoHealthyHabits
-